Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 458-470
DOI: 10.1111/apt.70811 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 07.07.2026. Verfasst von Rino Alvani Gani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jak…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Pyridines, Pyrimidines, Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eisai Indonesia.
Abstract (Originalsprache)
Background and Aim No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high‐risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited.
Methods
Restoring Sleep in End‐Stage Liver Disease (RESTORE) is a prospective, double‐blind, placebo‐controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo ( n = 28), 5 mg Lemborexant ( n = 28), and 10 mg Lemborexant ( n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2‐week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post‐crossover at week 4 to investigate rebound insomnia.
Results
Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: −7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: −8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: −23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post‐crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant.
Conclusion
Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow‐up are warranted to strengthen evidence. ClinicalTrials.gov: NCT07480096.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
ORCID-Profile: Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Valerie Josephine Dirjayanto
Förderung
- Eisai Indonesia
Zitieren
APA
Gani, R. A., Akbar, P., Hasan, I., Sulaiman, A. S., Lesmana, C. R. A., Kurniawan, J., Panjaitan, S. M., & Dirjayanto, V. J. (2026). Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics, 64(4), 458-470. https://doi.org/10.1111/apt.70811
Vancouver
Gani RA, Akbar P, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, et al. Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics. 2026;64(4):458-470. doi:10.1111/apt.70811
BibTeX
@article{Gani2026,
author = {Gani, Rino Alvani and Akbar, Pitt and Hasan, Irsan and Sulaiman, Andri Sanityoso and Lesmana, Cosmas Rinaldi Adithya and Kurniawan, Juferdy and Panjaitan, Sarah Melissa and Dirjayanto, Valerie Josephine},
title = {Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {4},
pages = {458--470},
doi = {10.1111/apt.70811}
}
EUVIMED